相关实验视频
Updated: Jan 13, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
[可注射和透皮胰岛素输送系统的进步]
Kaihui Li1, Xiuwen Zhang2, Zhen Gu2,3,4,5,6,7,8
1School of Pharmacy, Zhejiang University, State Key Laboratory of Advanced Drug Delivery and Release Systems, Hangzhou 310058, China. 12519055@zju.edu.cn.
概括
葡萄糖响应性胰岛素系统提供更好的血糖控制和降低低血糖的风险. 本综述涵盖可注射和透皮系统,重点关注其发展和临床转化潜力.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 内分泌学 在内分泌学.
背景情况:
- 传统的胰岛素治疗面临限制,包括延迟血糖控制和低血糖风险.
- 葡萄糖响应性胰岛素输送系统旨在动态感知血糖,并在需求时释放胰岛素.
研究的目的:
- 系统地审查近期可注射和透皮葡萄糖响应胰岛素输送系统的进展.
- 专注于载体结构,对葡萄糖反应的释放机制和制备技术.
- 要突出性能,安全性,生物相容性和患者坚持性方面的改进.
主要方法:
- 基于传感机制的系统分类 (葡萄糖氧化酶,葡萄糖结合分子,酸).
- 根据给药途径进行分类:注射和通过皮肤输送.
- 对文学进行系统审查,重点关注载体战略,释放机制和制备技术.
主要成果:
- 可注射系统利用对葡萄糖有反应的载体,实现稳定的生物可用性和与现有治疗方法的兼容性.
- 透皮系统利用微针阵列进行无痛,精确的胰岛素输送.
- 进展侧重于提高对葡萄糖的反应性能,治疗安全性,生物相容性和患者坚持治疗.
结论:
- 葡萄糖响应性胰岛素输送系统显著有望克服传统治疗的局限性.
- 需要进一步的研究和开发,以应对成功临床翻译的挑战.
- 这些系统为糖尿病管理的未来进步提供了宝贵的前景.
相关概念视频
Insulin Formulations: Types and Delivery
642
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
642
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Insulin: Dosing Regimen and Adverse Effects
673
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
673
Oral Hypoglycemic Agents: Glinides
593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593
Drug Delivery: Miscellaneous Routes
708
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
708
Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K

